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hTERT expression in melanocytic
lesions: an immunohistochemical study
on paraffin-embedded tissue
Background: Telomerase plays a role in the immortalization of cells
and carcinogenesis. Previous studies have yielded conflicting results on
whether human telomerase RNA (hTER) expression differs in nevi,
atypical nevi and melanomas using polymerase chain reaction-based
telomeric repeat amplification protocol or in situ hybridization assays.
The aim of this study was to evaluate human telomerase reverse
transcriptase (hTERT) staining in melanocytic lesions on paraffin-
embedded tissues.
Methods: Paraffin-embedded sections from 12 acquired nevi, seven
dysplastic nevi, 11 Spitz nevi, eight primary invasive melanomas, and
three metastatic melanomas were studied for staining intensity (0–3þ)
and percentage of labeled cells with anti-hTERT.
Results: hTERT staining was observed in most cells (>75%), in all
but three lesions, and was of greater intensity in the nucleus, especially
the nucleolus, compared with the cytoplasm. Spitz nevi tended to have
weaker hTERT staining (mean ¼ 1.7) compared with acquired nevi
(mean ¼ 2.2), dysplastic nevi (mean ¼ 2.4), primary melanomas
(mean ¼ 2.4), or metastatic melanomas (mean ¼ 3).
Conclusions: Although telomerase activity was weaker in Spitz nevi,
there was overlap with other nevi and primary invasive melanomas in
our small series. Thus, hTERT expression does not appear to be a
reliable adjunct to the histological diagnosis of primary melanocytic
lesions.
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Telomeres are composed of tandem nucleotide
repeats (TTAGGG)n and are located on the termini
of chromosomes in all vertebrates. The role of telo-
meres is to protect chromosomes from degradation
and aberrant recombination during replication.1–5
Telomerase is a ribonucleoprotein DNA polymerase
that is responsible for maintaining the length of
telomeres on the end of chromosomes.6,7 This
enzyme is repressed in human somatic cells, with a
few exceptions, resulting in progressive loss of
telomeres and shortening of the chromosome with
successive cell divisions. Eventually, chromosomes
reach a critical length at which cell division ceases,
senescence begins, and the cell ultimately undergoes
apoptosis or cell death.8,9 In contrast, telomerase
activity is detectable in germline cells, somatic cells
during fetal development, germinal centers of lymph
nodes, regenerative epithelium of the gastrointest-
inal tract, proliferative endometrium, the bulge
region of hair follicles, and stem cells of the epider-
mis.10–15
Immortalized cell lines of a vast array of human
cancers, such as breast, colorectal and ovarian can-
cer, and melanoma, for example, have been shown
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to possess telomerase activity.16–22 Additional cuta-
neous neoplasms that have been shown to express
telomerase activity include basal cell carcinoma,
in situ and invasive squamous cell carcinoma, eccrine
carcinoma, poroma and porocarcinoma, trichilem-
mal carcinoma, and seborrheic keratosis.23–25 Thus,
telomerase appears to play a role in the unregulated
proliferation and ultimate immortality of somatic
cells.26–30
Previous studies evaluating human telomerase
RNA (hTER) expression in melanocytic lesions of
the skin, including various types of nevi and mela-
nomas, using polymerase chain reaction (PCR)-
based telomeric repeat amplification protocol
(TRAP) or in situ hybridization assays have yielded
conflicting results. Rudolph et al.31 demonstrated
distinct differences in telomerase activity between
nevi and melanomas, but not between common
nevi and dysplastic nevi, by TRAP assay, and that
levels correlated with tumor progression in melano-
mas. Ramirez et al.32 also found that telomerase
RNA levels increased from benign to malignant
melanocytic lesions and from primary to metastatic
melanomas by TRAP assay and confirmed the
enzyme expression in tumor cells by in situ hybridi-
zation on paraffin-embedded tissue sections. In con-
trast, Guttman-Yassky et al.33 reported similar
moderate-to-high intensity RNA levels in Spitz
nevi, ordinary nevi, and melanomas by in situ hybri-
dization for hTER.
To our knowledge, telomerase activity has not
been evaluated on paraffin-embedded tissue sections
in melanocytic lesions. The goal of this study was to
evaluate a spectrum of melanocytic lesions, includ-
ing common acquired nevi, Spitz nevi, atypical (dys-
plastic) nevi, primary invasive melanomas, and
metastatic melanomas, to determine whether differ-
ences exist in the intensity or pattern of human
telomerase reverse transcriptase (hTERT) expres-
sion between these lesions and whether this antibody
has diagnostic utility in their evaluation.
Materials and methods
Formalin-fixed, paraffin-embedded archival tissue
blocks from 30 benign melanocytic lesions (12 com-
mon acquired nevi, seven dysplastic nevi, and 11
Spitz nevi), and 11 melanomas (8 primary invasive
and 3 metastatic) were retrieved following a
SNOMED search of our laboratory data system.
The diagnoses were rendered by one of three staff
dermatopathologists on the Dermatopathology
Service at the University of Michigan.
Immunohistochemical staining for hTERT was
performed on all 41 melanocytic lesions. Briefly,
4-mm thick sections were cut and placed on charged
slides. The slides were deparaffinized, rehydrated,
and endogenous peroxidases were blocked by
incubation with 3% H2O2. Antigen retrieval was
accomplished by incubating the slides with 10-mM
citrate buffer at pH 6.0 and microwaving for
20 min. The slides were stained with a primary
monoclonal antibody to hTERT (1:50; Novocastra,
Newcastle, UK). The primary antibody titer used in
this study was selected based on the dilution that
produced an optimum staining pattern as judged in
titration studies performed on tonsil and melanoma
tissue microarray controls and was in concord-
ance with the manufacturer’s recommendation.
Immunohistochemical staining was performed on a
DAKO Autostainer (DAKO, Carpinteria, CA)
using DAKO LSABþ and 3,30-diaminobenzidine
as the chromogen. The slides were counterstained
with Mayer’s hematoxylin. Positive and negative
control slides were performed. The extent of stain-
ing, as determined by the percentage of lesional cells
(0/–, 1–25%/1þ, 26–75%/2þ, and >75%/3þ)
and the intensity (negative/0, weak/1þ, moder-
ate/2þ, and strong/3þ), was independently evalu-
ated by three observers, including two board
certified dermatopathologists (LDS and DRF) and
were recorded semiquantitatively and with good
concordance.
The Institutional Review Board of the University
of Michigan approved this study.
Results
The percentage of lesional cells expressing hTERT
and the intensity of staining are presented in
Tables 1 and 2, respectively. hTERT staining was
identified in all 41 melanocytic lesions. The vast
majority (>75%) of lesional cells expressed hTERT
in the melanocytic lesions, with the exception of one
acquired nevus, one Spitz nevus, and one dysplastic
nevus, which showed 25–75% of lesional cells stain-
ing. The pattern of hTERT expression was uniform
throughout the lesion, with approximately the same
degree of staining in the lower half as the upper half
of the dermal component in benign melanocytic
nevi and melanomas. The nucleus, especially the
nucleolus, showed greater staining intensity com-
pared with the cytoplasm of the melanocytes.
The staining intensity varied between the differ-
ent types of melanocytic lesions. In general, the least
amount of hTERT staining was seen in Spitz nevi
(mean ¼ 1.7). In fact, weak (1þ) labeling for
hTERT was observed in five of 11 Spitz nevi
(Fig. 1A), whereas six of 11 Spitz nevi showed mod-
erate (2þ) or strong (3þ) staining. Common
acquired nevi that were either compound or intra-
dermal showed greater staining (mean ¼ 2.2) than
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Spitz nevi, with only two of 12 examples possessing
weak (1þ) hTERT staining and 10 of 12 examples
having moderate (2þ) or strong (3þ) staining
(Fig. 1B). Dysplastic nevi and primary invasive
melanomas had the same average (mean ¼ 2.4) for
hTERT staining, although one invasive melanoma
had weak (1þ) staining in contrast to no dysplastic
nevi. On the other hand, a slightly higher percent-
age of invasive melanomas (4/8, 50%) than dysplas-
tic nevi (3/7, 43%) had strong (3þ) labeling
(Fig. 1C,D). Metastatic melanomas had the most
hTERT expression (mean ¼ 3), with strong (3þ)
expression in all three cases (Fig. 1E).
In the skin adjacent to the melanocytic lesions,
primarily nuclear staining for hTERT was observed
in all levels of the epidermis, hair follicle epithelium,
in particular the outer few layers along the entire
length of the follicle and diffusely in hair bulbs,
sebaceous lobules, sweat duct and glandular epithe-
lium, and vascular endothelium to at least a moder-
ate (2þ) degree (Fig. 1F). Positive and negative
control slides were appropriate.
Discussion
Our study has proven that hTERT can be reliably
detected in paraffin-embedded tissue sections in a
variety of melanocytic lesions that includes both nevi
(common acquired and Spitz) and melanomas. This
method is very useful because, in contrast to the
PCR-based TRAP assay employed in some of the
previous studies, the staining can be visualized in the
cells of interest. Moreover, it is clear that many
normal tissue structures in skin reproducibly express
telomerase. In agreement with the observations of
Guttman-Yassky et al., we observed telomerase
expression in keratinocytes at all levels of the epi-
dermis and within sebaceous glands, hair follicles,
and sweat glands, although they employed in situ
hybridization for hTER expression, and we evalu-
ated hTERT expression by immunohistochemistry.
We are unaware of any immunohistochemical stu-
dies, to date, that have evaluated hTERT staining
on skin lesions. It is not surprising that hTERT is
seen predominantly in the nucleolus of the nucleus,
considering that the target of the antibody is a
ribonucleoprotein DNA polymerase.
In this series of 41 melanocytic lesions, we were
able to demonstrate hTERT staining in all lesions.
A trend of increasing mean hTERT expression from
nevi to dysplastic nevi and primary invasive mela-
nomas to metastatic melanomas was observed. This
finding suggests a role for telomerase in tumor pro-
gression, which is not surprising based on previously
published data. For instance, Ramirez et al.32
demonstrated increased mean levels of telomerase
activity by the PCR-based TRAP assay for subcuta-
neous and nodal metastases of melanoma when
compared with primary invasive melanomas and
also with increasing Clark’s level for the primary
invasive melanomas. Subsequently, Glaessl et al.34
reported significant differences in percentage of
cases with positive telomerase levels by a PCR-
based TRAP ELISA assay for metastatic melano-
mas (92%), primary invasive melanomas (90%), and
atypical nevi (80%) compared with common nevi
(28%) and normal skin (12%). Mirraco et al. also
demonstrated increasing mean telomerase activity
using a PCR-based TRAP assay from benign nevi
to dysplastic nevi to invasive melanomas to meta-
static melanomas.35 Finally, Rudolph and collea-
gues31 showed similar telomerase activity between
common and dysplastic nevi, but the levels were
much lower than for melanomas, although they
noted that all three groups had overlapping ranges.
Our findings are essentially in agreement with these
observers, although, in comparison with Rudolph
et al. our dysplastic nevus group showed similar
mean telomerase expression to primary invasive
melanomas and slightly greater than common
acquired nevi. In contrast to Guttman-Yassky et al.
who showed moderate-to-high hTER expression in
Spitz nevi, ordinary nevi, and melanomas,33 we
found the lowest semiquantitative hTERT staining
in our Spitz nevus group. Our finding of the lowest
mean telomerase activity in the Spitz nevus group is
similar to Tosi and colleagues.36 However, their
Spitz nevus group did not have an overlapping
range of mean relative telomerase activity compared
with their melanoma groups by TRAP assay,
whereas our Spitz nevus group did overlap with
Table 1. The intensity of hTERT protein expression in skin biopsies of
melanocytic lesions
1þ 2þ 3þ Mean
Acquired nevi 2 6 4 2.2
Spitz nevi 5 4 2 1.7
Dysplastic nevi 0 4 3 2.4
Melanoma 1 3 4 2.4
Metastatic melanoma 0 0 3 3.0
1þ ¼ weak; 2þ ¼ moderate; 3þ ¼ strong.
Table 2. The extent of hTERT protein expression in skin biopsies of
melanocytic lesions
1þ 2þ 3þ Mean
Acquired nevi 0 1 11 2.9
Spitz nevi 0 1 10 2.9
Dysplastic nevi 0 1 6 2.9
Melanoma 0 0 8 3.0
Metastatic melanoma 0 0 3 3.0
1þ ¼ 1–25% of lesional cells; 2þ ¼ 26–75% of lesional cells;
3þ  75% of lesional cells.
Fullen et al.
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our melanoma group with respect to immunostain
intensity for hTERT.
On the basis of significant differences in telomer-
ase activity between nevi and melanomas in some
studies and the recent availability of a primary anti-
body to hTERT for immunohistochemical staining
on paraffin-embedded sections, we were interested
in evaluating the staining pattern and intensity of
hTERT in a spectrum of melanocytic lesions to
determine whether this antibody had diagnostic uti-
lity. With the exception of metastatic melanomas,
which showed uniformly strong hTERT staining in
all cases, there was considerable overlap in staining
intensity among the remaining groups, including
with the metastatic melanoma group in this study.
Thus, hTERT expression, unfortunately, is not a
reliable discriminator between benign and malig-
nant melanocytic lesions in paraffin-embedded tis-
sues and, therefore, does not appear to have a role
as an adjunct to the histological differential diag-
nosis of melanocytic lesions. However, it is possible
that this antibody may prove useful as a prognostic
marker for melanoma or specific subtypes or to iden-
tify lesions that would be amenable to specific ther-
apy that would inhibit telomerase. The difficulty in
the latter instance is that normal skin structures have
telomerase activity, suggesting that there is potential
for untoward side effects unless telomerase activity is
coupled to a melanoma-specific target mechanism.
In summary, hTERT staining can be detected in
a broad spectrum of melanocytic lesions, as well as
some normal skin structures. A trend of increasing
mean hTERT staining from benign nevi to atypical
nevi and invasive melanoma to metastatic mela-
noma suggests a role in tumor progression, in keep-
ing with previous observations. Finally, this antibody
does not appear to have a role in diagnostic pathol-
ogy for the determination between a benign and
malignant melanocytic lesion for a given case,
within the limitations of the specific types of mela-
nocytic lesions studied in this series. The potential
role of immunohistochemical staining for hTERT







Fig. 1. Human telomerase reverse tran-
scriptase (hTERT) protein is expressed in
skin biopsies of melanocytic lesions. (A)
Spitz nevus with 1þ nuclear staining. (B)
Intradermal nevus with 3þ nuclear staining.
(C) Dysplastic compound nevus with 3þ
nuclear staining. (D) Primary invasive mela-
noma with 3þ nuclear staining. (E) Dermal
satellite metastasis of melanoma with 3þ
nuclear staining. (F) Keratinocyte nuclei of
the epidermis stain positively for hTERT in
this compound nevus.
hTERT immunostain in melanocytic lesions
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